Affinity Asset Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Affinity Asset Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$96.3M	Sell	1,595,000 -80,000	-5%	-$4.44M	4.35%	4
2026 Q1	$97.4M	Buy	1,675,000 +425,000	+34%	+$19.6M	5.03%	3
2025 Q4	$56M	Sell	1,250,000 -150,000	-11%	-$6.3M	3.19%	7
2025 Q3	$56.2M	Buy	1,400,000 +300,000	+27%	+$10.6M	4.9%	4
2025 Q2	$34.4M	Sell	1,100,000 -228,175	-17%	-$7.44M	4.7%	3
2025 Q1	$44.6M	Buy	1,328,175 +166,938	+14%	+$6.34M	4.25%	3
2024 Q4	$45.5M	Buy	1,161,237 +17,216	+2%	+$712K	6.1%	2
2024 Q3	$45M	Buy	1,144,021 +149,794	+15%	+$6.04M	6.15%	1
2024 Q2	$38.8M	Buy	994,227 +156,840	+19%	+$6.27M	4.47%	2
2024 Q1	$36M	Buy	837,387 +377,387	+82%	+$17.4M	4.46%	4
2023 Q4	$21.2M	Buy	460,000 +159,562	+53%	+$5.64M	3.87%	5
2023 Q3	$10.3M	Buy	300,438 +240,062	+398%	+$8.98M	2.89%	12
2023 Q2	$2.32M	Sell	60,376 -29,624	-33%	-$1.18M	0.81%	35
2023 Q1	$3.22M	Buy	90,000 +40,000	+80%	+$1.48M	1.06%	29
2022 Q4	$1.97M	Buy	+50,000	New	+$1.82M	0.77%	40
2022 Q2	–	Sell	-80,000	Closed	-$2.45M	–	70
2022 Q1	$2.45M	Sell	80,000 -70,500	-47%	-$2.11M	0.39%	35
2021 Q4	$4.7M	Buy	150,500 +100,500	+201%	+$3M	1.71%	26
2021 Q3	$764K	Buy	+50,000	New	+$869K	0.19%	64

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Affinity Asset Advisors's XENE Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Xenon Pharmaceuticals (XENE) stake by 4.8% in Q2 2026, selling an estimated $4.44M and leaving 1,595,000 shares worth $96.3M. The position accounts for 4.35% of the portfolio, ranked #4.

Affinity Asset Advisors first reported a position in XENE in Q3 2021 and has held it in 18 quarters since. The position peaked at $97.4M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Affinity Asset Advisors held 1,595,000 shares of Xenon Pharmaceuticals worth $96.3M as of Q2 2026.
Affinity Asset Advisors sold 80,000 Xenon Pharmaceuticals shares in Q2 2026, an estimated $4.44M.
Xenon Pharmaceuticals made up 4.35% of Affinity Asset Advisors's portfolio in Q2 2026, its #4 holding.
Affinity Asset Advisors first reported a position in Xenon Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
Affinity Asset Advisors's Xenon Pharmaceuticals position peaked at $97.4M in Q1 2026.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.